Payment overview · 2025
General Payments
$590.48
27 reported records · 9 companies
Healthcare provider profile · identity verified
Ashley Card Rogers, RN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · STATESVILLE, NC · NPI 1497936009
Verified facts
What the public records show
CMS Open Payments records show Ashley Card Rogers, RN received $590.48 in general payments during 2025 across 27 reported records.
Gilead Sciences, Inc. accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $182.20 | 30.9% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.71 | 25.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.25 | 12.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.28 | 11.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.46 | 6.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.98 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.60 | 3.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.26 | 3.1% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $14.74 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $590.48 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $134.63 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.72 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 173 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
173 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 286 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 277 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 182 | 51 |
| Ozempic | Semaglutide | 173 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 53 |
| Furosemide | Furosemide | 156 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 36 |
| Jardiance | Empagliflozin | 124 | 33 |
| Carvedilol | Carvedilol | 122 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 30 |
| Losartan Potassium | Losartan Potassium | 106 | 38 |
| Omeprazole | Omeprazole | 104 | 34 |
| Montelukast Sodium | Montelukast Sodium | 99 | 32 |
| Trazodone Hcl | Trazodone Hcl | 99 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 22 |
| Lisinopril | Lisinopril | 83 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 25 |
| Metformin Hcl Er | Metformin Hcl | 81 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 26 |
| Metformin Hcl | Metformin Hcl | 78 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 23 |
| Sertraline Hcl | Sertraline Hcl | 66 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 24 |
| Meloxicam | Meloxicam | 55 | 16 |
| Buspirone Hcl | Buspirone Hcl | 47 | 16 |
| Januvia | Sitagliptin Phosphate | 45 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 12 |
| Tramadol Hcl | Tramadol Hcl | 42 | 11 |
| Spironolactone | Spironolactone | 41 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 12 |
| Prednisone | Prednisone | 35 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Famotidine | Famotidine | 31 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | 13 |
| Valsartan | Valsartan | 31 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 16 |
| Fluconazole | Fluconazole | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Ramelteon | Ramelteon | 16 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $590.48 · 27 records | Gilead Sciences, Inc. | AIRSUPRA, APRETUDE, AREXVY, Cologuard Collection Kit, MAVYRET, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, VRAYLAR, Wegovy, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error